Abstract Library

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#4081 The risk of venous thromboembolism in neuroendocrine neoplasms: A single center experience

Introduction: Neuroendocrine Neoplasms (NENs) are a very heterogeneous group of tumors. Venous thromboembolism (VTE) is a common complication in cancer patients and one of the leading causes of mortality. There is a lack of data regarding the incidence and the impact of VTE in patients with NENs.

Conference:

Presenting Author: Belabdi D

Authors: Belabdi D, Bala N, Bouferoum L, Ou M,

Keywords: Neuroendocrine neoplasm, Venous thromboembolism,

#4062 Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine neoplasms (NEN)

Introduction: VTE is a significant complication in oncology and one of the primary causes of cancer-related mortality. Few studies have addressed VTE in pts with NEN, with an estimated incidence of 7.5% in the literature. Nevertheless, there is no evidence from large datasets.

Conference:

Presenting Author:

Authors: Hernando Cubero J, Gutierrez-Gordo M, Roca-Herrera M, García-Álvarez A, Serradell S,

Keywords: Thrombosis, Heparin, Splenic thrombosis,

#3916 Temozolomide as second and subsequent lines of treatment in metastatic adrenocortical cancer: Prospective phase II clinical trial

Introduction: Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. There are still no effective options for 2nd and subsequent lines of chemotherapy (ChT). Despite promising results of retrospective study with temozolomide (Tem), no prospective studies evaluating Tem efficacy have been published yet.

Conference:

Presenting Author: Zhulikov Y

Authors: Zhulikov Y, Kovalenko E, Bokhyan V, Khoroshilov M, Gabrava M,

Keywords: adrenocortical cancer, temozolomide, mitotane,

#3821 Risk of venous thromboembolism in pancreatic neuroendocrine neoplasms

Introduction: Venous thromboembolism (VTE) is a leading cause of morbidity and death in cancer. The incidence of VTE is increased in different cancers such as pancreatic ductal adenocarcinoma, however limited evidence is present this risk for pancreatic neuroendocrine neoplasms (pan-NENs).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Laffi A, Cella C, Rubino M, Spada F,

Keywords: Venous thromboembolism, pancreatic neuroendocrine tumor, pancreatic neuroendocrine carcinoma, NEN, VTE,